CWM
LCTX icon

CIBC World Markets’s Lineage Cell Therapeutics LCTX Stock Holding History

CIBC World Markets’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-39,837
Closed -$18K – 1760
2025
Q1 		$18K Buy
39,837
+26,012
+188% +$15.3K ﹤0.01% 1801
2024
Q4 		$6.95K Buy
+13,825
New +$10.2K ﹤0.01% 1324

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

CIBC World Markets's LCTX Position: Q2 2025 in Review

CIBC World Markets sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 39,837 shares — an estimated $18K sold.

CIBC World Markets first reported a position in LCTX in Q4 2024 and held it in 2 quarters. The position peaked at $18K in Q1 2025. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

  • CIBC World Markets reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CIBC World Markets sold 39,837 Lineage Cell Therapeutics shares in Q2 2025, an estimated $18K.
  • CIBC World Markets first reported a position in Lineage Cell Therapeutics in Q4 2024 and held it in 2 quarters.
  • CIBC World Markets's Lineage Cell Therapeutics position peaked at $18K in Q1 2025.
  • 129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.